Gabapentin Capsule
Product Images NDC 55154-8194

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 55154-8194). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ahp58001

Image shows two white capsules of Gabapentin with imprint '216' in blue on one side. Both capsules are smooth and oblong, without scored lines, on a measurement grid background. No other markings or colors are visible.*

FDA Label Image

Ahp59101

Image shows two yellow capsules of Gabapentin, an oral medication. One capsule is marked with the imprint '215' in blue. Capsules are smooth and elongated, approximately 18 mm in length. No further labeling or packaging is visible in the image.*

FDA Label Image

Bag Label (D4f21e97 5e55 44c9 9b31 5f79ac2eb512 00)

Drug facts label for Gabapentin capsules, USP 300 mg, with 10 capsules. Includes dosage statement, storage instructions (20° to 25° C), child safety warnings, and dispensing instructions for pharmacists. Also provides distributor and labeling information from American Health Packaging and Cardinal Health.*

FDA Label Image

Bag Label (D4f21e97 5e55 44c9 9b31 5f79ac2eb512 01)

Gabapentin Capsules, USP 100 mg label with a package count of 10 capsules. The label includes storage instructions, a warning that the unit dose package is not child resistant, and is intended for institutional use only. Distributed by Cardinal Health 107, LLC and American Health Packaging.*

FDA Label Image

Cockcroft And Gault Equation (Equation)

A formula for calculating creatinine clearance (CLCr) based on age, weight, serum creatinine, and a factor for female patients. This panel provides a mathematical expression used in clinical contexts but does not contain specific drug information.*

FDA Label Image

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (Figure1)

A line graph depicting mean pain scores over an 8-week period comparing placebo and Gabapentin 3600 mg/day. The x-axis shows weeks, divided into a 4-week dose titration period and a 4-week fixed dose period. The y-axis ranges from 0 to 10 representing mean pain scores. Gabapentin group shows a downward trend in pain scores, while placebo remains relatively stable.*

FDA Label Image

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (Figure2)

A line graph showing mean pain scores over a 7-week period comparing placebo and two doses of Gabapentin (1800 mg/day and 2400 mg/day). The x-axis represents weeks, with a 3-week dose titration period followed by a 4-week fixed dose period. The y-axis shows pain scores from 0 to 10, illustrating reduced pain scores for both Gabapentin doses compared to placebo.*

FDA Label Image

Figure 3. Proportion Of Responders (patients With ≥ 50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (Figure3)

A bar graph titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies.' It compares response rates for placebo (PBO) and gabapentin (GBP) at different doses across two studies. Study 1 shows 12% for PBO and 29% for GBP 3600 mg. Study 2 shows 14% for PBO, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Significance indicators (** and ***) denote p-values less than 0.01 and 0.001, respectively.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥ 12 Years Of Age With Partial Seizures (Figure4)

A scatter plot chart showing percentage difference on the y-axis and daily dose in mg on the x-axis for Gabapentin studies. It compares three studies labeled as Study a, Study b, and Study c across doses of approximately 600, 900, 1200, and 1800 mg, with Study a and b showing higher differences at the highest and intermediate doses respectively.*

FDA Label Image

Structural Formula (Structure)

Chemical structure of gabapentin, showing a cyclohexane ring bonded to groups containing amino (CH2NH2) and carboxyl (CH2CO2H) functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.